bluuebunny/crossref_metadata_2025_split huggingface dataset:
#6193 MULTICENTER RETROSPECTIVE STUDY EVALUATING THE CLINICAL PICTURE AND OUTCOME OF THE SARS-COV2 INFECTION AMONG PATIENTS WITH GLOMERULAR DISEASES
Authors: Lionaki Sophia , Marinaki Smaragdi , Katartzi Kostantia , Galitsiou Dimitra , Moustakas George , Dounousi Eva , Flouda Sophia , Boumpas Dimitrios , Liakopoulos Vassilios , Vaios Vasileios , Karagiannis Minas , Kalogeropoulos Petros , Mpintas Christos , Pantzopoulou Evaggelia , Giannakopoulos Panagiotis , Gkika-Zervou Louiza , Papasotiriou Marios , Goumenos Dimitrios , Venetsanopoulou Aliki , Voulgari Paraskevi , Grapsa Eirini , Andronikidi E , Stylianou Konstantinos , Panagoutsos Stylianos , Boletis Ioannis 
Published: June 2023

Abstract

Background and Aims
This is a retrospective study aiming to describe the clinical picture and outcome of sars-cov2 infection in patients with glomerular diseases (GD) and its impact in the probability of relapse of the primary disease.

Methods
Patients with biopsy-broven GD, who had been infected by sars-cov2 were studied. Patients who ended up in end-stage kidney disease prior to infection were excluded. We recorded demographics, histopathological diagnosis, past medical history, immunosuppressive regimens which were given for the GD, status of GD at the time of infection, clinical picture and outcome of the infection including specific symptoms, requirement for hospitalization, duration of hospitalization and outcome of Covid-19. The probability of relapse following Covid-19 was also estimated in patients who were infected and those who did not.

Results
To date 312 patients have been included in the study, of whom 214 (68,5%) were diagnosed with Covid-19, while the remaining 98 did not. Infected patients were younger compared with those not infected [44 (28-59.75) vs. 53 (38-64) years, p&lt;0.001]. The mean time from the diagnostic biopsy to Covid-19 was 67,6(±59,3) months. 82,5% of the infected patients were vaccinated against sars-cov2 and 49,1% were treated with immunosuppressive therapy at vaccination. 28(13%) of the infected patients required admission to hospital, with a mean duration of 8,3(±5,1) days. 84,2% of the infected patients experienced complete recovery of the infection, 4 (1,9%) died due to Covid-19 and 24 (11%) had Covid-19 related symptoms for more than 3 months. Among patients who had achieved remission of the GD prior to the infection, the frequency of relapse of the primary disease was higher in patients with Covid-19 versus not infected patients (11.9% vs. 2.1%, p = 0.007).

Conclusions
According to our findings, the sars-cov2 infection appears to have a significant impact in patients with GD not only due to the increased morbidity but also by increasing the probability for relapse of the primary disease.
#6235 ELEVATED PLASMA ANGIOPOETIN-2 PREDICT THE NEED FOR DIALYSIS INITIATION IN PATIENTS WITH CKD 4 AND 5 WITHIN TWO YEARS
Authors: Szymczak Anna , Kusztal Mariusz , Krzysztof Letachowicz , Gołębiowski Tomasz , Gozdzik Anna , Koscielska-Kasprzak Katarzyna , Tukiendorf Andrzej , Krajewska Magdalena 
Published: June 2023

Abstract

Background and Aims
Volume status, congestion and endothelial activation/injury were found to play a role in GFR decline and CKD progression. This pilot study aimed to determine whether the plasma markers of endothelial injury and activation as well as markers of fluid overload could serve as independent predictors for dialysis initiation in stable patients with CKD 4 and 5 and preserved EF.

Method
This prospective study was conducted from March 2019 to March 2022 and enrolled consecutive patients with GFR &lt;30ml/min/1.72 m2 and preserved LVEF. Plasma levels of angiopoietin (Ang)-2, Vascular Endothelial Growth Factor-C (VEGF-C), Vascular Cell Adhesion Molecule-1 (VCAM-1), Copeptin (CPP), beta-trace protein (BTP), brain natriuretic peptide (BNP), cardiac troponin I (cTnI) were measured (Quantikine ELISA;R&D Systems Inc, Minneapolis, MN). Clinical markers of congestion were also recorded: lung US (B-lines), bioimpedance (ECV/ICV), echocardiography with global longitudinal strain (GLS), pulse wave velocity (PWV). Study outcome was need to initiate dialysis during 24-months follow-up.

Results
We analyzed a total of 105 patients with mean eGFR 21,3 ml/min/1.73m. The median age at enrollment was 52 (+/-14.8) years and 65% of the patients were male; 79% were hypertensive and 24% were diabetic. A positive correlation between concentration of Ang-2 and VCAM-1 and BTP was observed. Ang-2 concentration correlated positively with BNP, TnT, sCr, e/e’, ECV/ICV. Over a follow-up period of 24 months, the deterioration of renal function was observed in 47 patients (58%), 31 (38%) presented stable or ameliorated renal function and 24 on maintenance dialysis formed a control group. In Kaplan-Meier analysis significant impact of Ang-2 on renal survival (Figure) was found. Namely, 72% of patients with Ang-2 concentrations below the median (3.15 ng/ml) survived without dialysis for two years, compared to 42% of those with Ang-2 concentrations above the median. Such impact was not observed for GFR, VCAM, CCP, VEGF-C, BTP.

Conclusion
Endothelial activation, quantified by plasma levels of Ang-2 may play an important role in GFR decline and need for dialysis initiation in patients with CKD 4 and 5.
#6297 LAPAROSCOPIC VERSUS OPEN-SURGERY CATHETER PLACEMENT IN PERITONEAL DIALYSIS PATIENTS: A META-ANALYSIS OF OUTCOMES
Authors: Abdijalil Guled 
Published: June 2023

Abstract

Background and Aims
The peritoneal dialysis catheter (PDC) can be placed either through the laparoscopic technique, percutaneous technique or surgical procedures. The utilization of these PDC placement procedures is based on successful placement and reduced risk of development of complications. The main objective of this study was to compare the complications associated with laparoscopic vs. open-surgery PDC placement procedure.

Method
Literature for this review was obtained from all databases. to studies published in the period between 1998 and 2019 using Stata Version 12.

Results
The results showed significant difference in catheter malfunction between the laparoscopic and open-surgery group (relative risk [RR] = 0.58; 95% CI: 0.42–0.8; P = 0.031). Furthermore, there was no significant statistical difference in dialysate leakage (RR = 0.77; 95% CI: 0.51–1.17, P = 0.116) peritonitis (RR = 0.8; 95% CI: 0.6–1.06, P = 0.349) and exit-site infection (RR = 0.84; 95% CI: 0.65–1.09, P = 0.834) between the laparoscopic and open-surgery PDC placement groups.

Conclusion
The laparoscopic PDC placement procedure was superior to open surgery in regards to catheter malfunction. Additionally, the choice of treatment procedure should put in consideration factors such as cost and comfortability of the patient.
#6332 INFLUENCE OF NUTRITIONAL STATUS ON THE INCREASE IN CARDIOVASCULAR RISK AND THE RISK OF KIDNEY DAMAGE IN COMORBIDITY OF HYPERTENSION AND COPD
Authors: Boiko Olha , Rodionova Viktoriia 
Published: June 2023

Abstract

Background and Aims
It is widely known that obesity is a modulated additional factor in increasing cardiovascular risk in patients with hypertension. Since the number of patients with comorbidity of arterial hypertension and COPD is increasing, the question of the relationship between nutritional status and cardiovascular risk remains relevant. Purpose of the study: to determine the role of nutritional status indicators in the formation of cardiovascular risk in patients with comorbidity of hypertension and COPD.

Method
101 patients were included in a cross-sectional study: 32 patients with comorbidity of hypertension and COPD (Gr I), 43 patients with hypertension (Gr II), and 26 patients with chronic obstructive pulmonary disease (Gr III). Exclusion criteria: informed consent of the patient to processing of personal data, Hypertension stage II, 1-3 degree, COPD A - C clinical groups(stable phase), age≥40 years. Exclusion criteria: age≥80 years, myocardial infarction and cerebral circulatory disorders, kidney diseases (polycystosis, developmental abnormalities, glomerulonephritis, pyelonephritis), diabetes mellitus, cancer, GFR &lt; 30 ml/min. Patients underwent general clinical examination, determined nutritional status by anthropometric study and bioimpedancemetry, assessed the renal function by laboratory examination of blood. Methods of parametric and nonparametric statistics were used.

Results
A high cardiovascular risk in Gr I was in 22 (68,8%) patients, in Gr II - in 27 (62,9%) patients and in Gr III - in 10 (38,5%) patients. GFR in Gr I was 67,5 (57,0;77,0) ml/min, in Gr II -70.6 (57.0; 83.0) ml/min, and in Gr III - 82.5 (70.0;89.0) ml/min (p = 0.02). BMI in Gr I was 30.2 (26.5;35.0) kg/m2, in GrII - 29.7 (26.3;33.9) kg/m2, in GrIII - 26.8 (24.6;29.6) kg/m2. Percentage of adipose tissue in Gr I was 35.1 (30.0;41.7), in Gr II-38.2 (32.4;42.1) and in Gr III - 27.7 (21.0;34.1) (p = 0.01). The total muscle tissue in Gr I was 28,6 (24,6;30,6)%, in Gr II - 28,5 (25,0;31,2)%, in Gr III - 32,1 (27,8;35,3)%(p = 0.1), visceral fat in Gr I was 11,0 (8,0;14,0)%, in Gr II- 11,0 (9,0;15,0) %, in Gr III- 9,0 (6,0;13,0) %(p = 0.1); sarcopenia index in Gr I was 77,8(61,6;86,2), in Gr II- 77,8(66,1;101,8), in Gr III- 90,6(86,0;98,6)(p = 0,1). In Gr I, correlations were found: negative between GFR and high cardiovascular risk (R = -0.6), positive - between sarcopenia index, visceral fat and high cardiovascular risk (R = 0.5; 0.6), negative - between the amount of muscle tissue and high cardiovascular risk in patients (R = -0.5) (p&lt;0,05).

Conclusion
In patients with a comorbidity of hypertension and COPD, along with an increase in the amount of adipose tissue and visceral fat, the amount of muscle tissue decreases, which leads to sarcopenic obesity. Sarcopenic obesity is associated with high cardiovascular risk and worsening of renal function, which also leads to an increased risk of cardiovascular complications.
#6346 CANCER RELATIVE SURVIVAL IN DIALYSIS AND KIDNEY TRANSPLANT RECIPIENTS: A POPULATION-BASED STUDY IN AUSTRALIA AND NEW ZEALAND 1980-2019
Authors: Oliveras Laia , Rosales Brenda , Montero Nuria , Melilli Edoardo , Cruzado Josep , Webster Angela , Mata Nicole De La 
Published: June 2023

Abstract

Background and Aims
Cancer survival in the general population has improved over time. Kidney failure population have a higher incidence of cancer with increased mortality. Relative survival following cancer diagnosis can provide more insight into the excess mortality directly or indirectly attributed to cancer in the kidney failure population.

Method
We estimated and compared the relative survival for dialysis patients, kidney transplant recipients and general population with cancer in Australia and New Zealand from 1980 to 2019. The general population was reference group for background mortality, matching on sex, age, calendar year and country. We used Poisson regression to quantify the excess mortality between these three groups with cancer.

Results
We included 4,089 dialysis patients and 3,253 kidney transplant recipients with an incident cancer. Dialysis patients were older, had a higher proportion of indigenous people and had more comorbidities than kidney transplant recipients. The kidney failure population had lower 5-year relative survival: 0.25 (95%CI: 0.23-0.26) for dialysis, 0.55 (95%CI: 0.53-0.57) for kidney transplant and 0.670 (95%CI: 0.669-0.670) in the general population with cancer (Figure 1). At any given time, dialysis patients had a 2.10 times higher adjusted excess mortality compared to the general population with cancer (2.10, 95%CI: 2.02-2.18), whereas kidney transplant recipients had no excess mortality (1.02, 95%CI: 0.97-1.08). Relative survival and excess mortality varied by cancer site: lung had the lowest relative survival rates, while kidney failure population with melanoma, breast and prostate cancers had the highest excess mortality. There were also sex differences: women had greater relative survival.

Conclusion
Relative survival was lower among the kidney failure population with incident cancer compared to the general population with cancer, for all-site and particularly for melanoma, breast and prostate cancer. Decreased survival may be due to poorer access to, more harm or less efficacy of treatments.
#6355 EFFECTS OF SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS ON HEART FAILURE IN CHRONIC KIDNEYDISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Alexandrou Maria Eleni , Tsitouridis Alexandros , Theodorakopoulou Marieta , Kamperidis Vasileios , Pella Eva , Sampani Erasmia , Xanthopoulos Andrew , Papagianni Aikaterini , Sarafidis Pantelis 
Published: June 2023

Abstract

Background and Aims
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors significantly reduce the risk for hospitalizations for heart failure (HF) in patients with diabetes, and HF; findings in patients with chronic kidney disease (CKD) are not uniform. Objectives: We aimed to perform a meta-analysis exploring the effect of SGLT-2 inhibitors on HF events in patients with CKD and across subgroups defined by baseline kidney function.

Method
A systematic search in major electronic databases was performed. Randomized controlled trials providing data on the effect of SGLT-2 inhibitors on the primary outcome, time to hospitalization or urgent visit for worsening HF in patients with prevalent CKD at baseline or across subgroups stratified by baseline estimated glomerular-filtration-rate (eGFR) were included.

Results
Twelve studies (n = 89,191 participants) were included in the meta-analysis. In patients with CKD, treatment with SGLT-2 inhibitors reduced the risk for HF events by 32% compared to placebo (hazard ratio [HR] 0.68;95%CI 0.63-0.73). Reduction in HF events with SGLT-2 inhibitors was more prominent in patients with eGFR&lt;60 ml/min/1.73m2 (HR 0.68; 95%CI 0.62-0.74) than in those with eGFR&gt; = 60 ml/min/1.73m2 (HR 0.76;95%CI 0.69-0.83). Subgroup analysis according to type of SGLT-2 inhibitor showed a consistent treatment effect across all studied agents (p subgroup-analysis = 0.44). Sensitivity analysis including data from studies including only diabetic patients showed an even more pronounced effect in eGFR subgroup&lt;60ml/min/1.73m2 (HR 0.62; 95%CI 0.54-0.70).

Conclusion
Treatment with SGLT-2 inhibitors led to a significant reduction in HF events in patients with CKD. These findings may change the landscape of HF treatment in patients with advanced CKD.
#6447 ASSOCIATION BETWEEN PHYSICAL ACTIVITY LEVEL AND A HISTORY OF FALLS IN PATIENTS ON HEMODIALYSIS
Authors: Lucinda Leda , de Jesus Luciana , Alvarenga Bárbara , de Castro Abner , Ávila Kéller , Garcia Rodrigo , Oliveira Cristino , Pinheiro Bruno , Reboredo Maycon Moura 
Published: June 2023

Abstract

Background and Aims
Patients with end-stage renal disease on hemodialysis have a lower physical activity level in daily life and a higher prevalence of sedentary lifestyle. Moreover, these patients have clinical, musculoskeletal, and physical function complications that contribute to a higher risk of falling. Therefore, the aim of this study was to evaluate the association between physical activity level and a history of falls in a retrospective 12-month interval in patients on hemodialysis.

Method
A retrospective study was conducted with patients aged ≥18 years who were undergoing regular hemodialysis treatment for at least three months. Patients were excluded if presented severe and unstable comorbidities, psychiatric or cognitive disorders, uncorrected visual impairments, and hospitalization in the past three months. The retrospective history of falls was assessed for the last 12 months, and a fall was defined as an “unexpected event in which the individual comes to rest on the ground, floor or lower level”. The daily step counts were recorded in the ActiGraph accelerometer (wGT3X-BT) during seven days, and analyzed by excluding the first and last day of recording and calculating the mean among the valid days (≥ 8 hours of wear time). Normality of data was analyzed using the Shapiro-Wilk test. The Student's t-test and the Mann-Whitney U test were used for between-group comparisons (patients with and without a history of falls). The univariate and multivariate linear regression models investigated the association between daily step counts and a history of falls. A p value &lt;0.05 was considered as statistically significant.

Results
This study included 103 patients (59.2 ± 12.6 years, 59.2% male). Of these patients, 49.5% had a history of falls. Patients with a history of falls showed lower prevalence of workers (9.8% vs. 26.9%, p = 0.025) and daily step counts [2989 (2595) vs. 4550 (2966) steps, p = 0.018], and higher educational level [9 (7) vs. 5 (5) years, p = 0.033] compared to patients without a history of falls. The univariate linear regression model showed that daily step counts was significantly associated with a history of falls (p = 0.017). After adjusting for age, gender, educational level, work status, hemoglobin, and diabetes mellitus, this association remained significant in multiple linear regression model with a coefficient of determination of 0.21 and an adjusted coefficient of determination of 0.16 (p = 0.001).

Conclusion
Physical activity level was associated with a history of falls in a retrospective 12-month interval in patients on hemodialysis.
#6500 MULTICENTER RETROSPECTIVE STUDY TO ASSESS THE CLINICAL PRESENTATION AND OUTCOME OF SARS-COV2 INFECTION IN PATIENTS WITH LUPUS NEPHRITIS
Authors: Petrou Dimitra , Katartzi Kostantia , Marinaki Smaragdi , Kriki Pelagia , Venetsanopoulou Aliki , Voulgari Paraskevi , Kalogeropoulos Petros , Agoranou Marilena , Sardeli Aggeliki , Panagoutsos Stylianos , Michelakis Ioannis , Boumpas Dimitrios , Boletis Ioannis , Lionaki Sophia 
Published: June 2023

Abstract

Background and Aims
The present study aims to describe the clinical presentation and outcome of SARS-CoV2 infection in patients with systemic lupus erythematosus (SLE) and renal involvement (LN).

Method
82 patients with biopsy-proven LN were retrospectively studied. 56 (68.3%) had a positive test for SARS-CoV2 at some point during the follow up time and were compared with 26 patients with SLE patients who had LN but were not infected with SARS-CoV2 in oedr toexplore the impact of SARS-CoV2 infection in the outcome of LN. Patients who had reached end-stage kidney disease before infection were excluded. Biopsy data, treatment, outcome of LN, clinical presentation of SARS-CoV2 infection and outcome were recorded.

Results
The mean age of the patients was 33 (±12.7) years and 85.3% were females. In the histopathological diagnosis there was proliferative LN in 43 (76.8%) cases. All patients had received immunosuppressive therapy and 89.2% had achieved remission of LN. 66.1% of patients were treated with immunosuppressive agenst at the time of diagnosis of the SARS-CoV2 infection. 94.6% of patients were tested due to symptoms while gradually all of the patients became symptomatic. 5 (9.01%) of patients required hospitalization mainly due to hypoxemia. 11 (19.6%) of patients received specific treatment for SARS-CoV2 infection, 91.6% of patients experienced complete recovery, 2 (3.57%) experienced prolonged symptomatology, and 1 (1,785%) died. 10.9% of patients with SARS-CoV2 infection, who were in remission before infection, experienced a relapse of LN in a mean time of 2.7(±2.1) months after the infection, while none of the patients without SARS-CoV2 infection relapsed in the same time period (p = 0.09).

Conclusion
SARS-CoV2 infection affects the morbidity of patients with SLE who have renal involvement and possibly the likelihood of relapse in those who have achieved remission prior to infection.
#6501 MULTICENTER STUDY ESTIMATING THE INCIDENCE OF ADVERSE EVENTS FROM SARS-CoV-2 VACCINATION AND ITS POTENTIAL EFFECT ON THE OUTCOME OF LUPUS NEPHRITIS
Authors: Lionaki Sophia , Petrou Dimitra , Flouda Sophia , Marinaki Smaragdi , Kriki Pelagia , Katartzi Kostantia , Venetsanopoulou Aliki , Voulgari Paraskevi , Agoranou Marilena , Gkiolas Konstantinos , Panagoutsos Stylianos , Fanouriakis Antonios , Boletis Ioannis 
Published: June 2023

Abstract

Background and Aims
The present study aimed to investigate the incidence of adverse events associated with SARS-CoV-2 vaccination in patients with a history of lupus nephritis (LN).

Method
Patients with biopsy-proven LN, who were vaccinated against SARS-CoV-2, were retrospectively studied. Patients who had reached end-stage kidney disease prior to vaccination were excluded. We recorded the histopathological diagnosis of LN, immunosuppressive regimens which were given for LN, the outcome of LN as a result of treatment, the tome interval form the diagnostic biopsy to vaccination, the number of doses each patient received, all reported adverse effects associated with the vaccine against SARS-CoV-2, including systemic and local adverse events. We also estimated the potential effect of the vaccination on the clinical course of LN among patients who were in remission.

Results
Ninety patients with systemic lupus erythematosus and renal involvement were included with a mean age of 31 (±18) years, of whom 80% were women. Proliferative LN was present in the diagnostic kidney biopsy in 68 (77.2%) cases and 91.8% of the included patients had achieved remission with treatment prior to vaccination. 86.7% of patients were vaccinated with 3 (2.75, 3) doses. The median time from diagnosis to vaccination was 59 (32-137) months and 70.5% of patients were receiving immunosuppression at the time of vaccination. 30.5% of patients reported systemic adverse reactions and 36.1% local adverse reactions at the site of administration. Among patients in remission who were vaccinated, only 1 (1.2%) patient experienced a relapse of LN within 3 weeks of the 1st dose. Three (3.4%) patients who had treatment-resistant disease experienced a worsening of SLE activity after vaccine administration.

Conclusion
In this cohort of patients with a history of LN, the SARS-CoV-2 vaccine appears safe, with no effect on the likelihood of disease recurrence among patients who have achieved remission.